NCT04097574已完成2 期
Phase II Study of NPO-13 in Patients Undergoing Colonoscopy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 158
- 试验地点
- 13
- 主要终点
- Proportion of No or Mild colonic spasm at the all sites of NPO-13 treatment
研究概览
简要总结
This study will investigate the safety, efficacy and dose-response of NPO-13 in subjects with moderate to severe colonic spasm during colonoscopy. An intraluminal spraying of NPO-13 dosed up to twice into ascending or sigmoid colon. The colonic spasm will be assessed by an independent committee using recorded video images. The study consists of a screening visit window, 1-day treatment phase and 1-week follow-up phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are between 20 and 85 years at the time of consent
- •Patients who need colonoscopy
排除标准
- •Patients with a history of abdominal surgical treatment (including the laparoscopic surgery) including the gynecology operation
- •Patients with contraindication to colonoscopy including the paralytic ileus
- •Patients with a history of shock or hypersensitivity to l-menthol or peppermint oil (mint oil)
- •Patient with contraindication to bowel cleansing preparation
- •Patient with contraindication to pain medicine and sedative medicine
- •Patient with contraindication to butylscopolamine bromide and glucagon
- •Patients on cancer treatment (chemotherapy or radiotherapy)
- •Patient with active inflammatory bowel disease or infectious enteritis
- •Patients who need sedative in colonoscopy
- •Patients who receives a therapeutic colonoscopy
- •Pregnant or lactating women, women of childbearing potential, or women who plan to become pregnant during the study
- •Patients who have received other investigational drugs within four months before consent or who are participating in other clinical studies
- •Patients otherwise ineligible for participation in the study in the investigator's or coinvestigator's opinion
结局指标
主要结局
Proportion of No or Mild colonic spasm at the all sites of NPO-13 treatment
时间窗: 3 minutes
The primary endpoint will be evaluated by third-party organization, using a four-grade scale: 1, No; 2, Mild; 3, Moderate; 4, Severe.
次要结局
- Change in colonic spasm before and after treatment of NPO-13 treatment(3 minutes)
- Adverse events and Adverse drug reactions(7 ± 3 days)
- Proportion of No or Mild colonic spasm at the each site of NPO-13 treatment(3 minutes)
- Time to effect(3 minutes)
- Difficulty of endoscopic observation(3 minutes)
研究者
研究点 (13)
Loading locations...
相似试验
已完成
2 期
Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total ColonoscopyBowel DiseaseNCT02265939Nihon Pharmaceutical Co., Ltd132
招募中
2 期
Prevention of Ototoxicity in NTM Patients Treated With IV AmikacinOtotoxicity, Drug-InducedNCT05730283Kevin Winthrop105
已完成
1 期
A Phase I Study of SOR-C13 in Patients With Advanced Solid TumorsAdvanced Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRefractory Ovarian CarcinomaRefractory Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8NCT03784677M.D. Anderson Cancer Center11
已完成
2 期
DP13 - A Phase II Study in Patients With Primary AldosteronismPrimary AldosteronismNCT04007406Damian Pharma AG35
已完成
2 期
Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive DisorderMajor Depressive DisorderNCT00514865Ono Pharma USA Inc278